Douglas S Williamson

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2021
Publications (10 Years): 3

Top Topics

Dna Damage Response

Tyrosine Kinase

Top Venues

Journal of medicinal chemistry

Scientific reports

Vernalis R&D Ltd

University of Manchester (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Vernalis R&D Ltd Jun 04 2001

United Kingdom

Senior Team Leader, Chemistry :: Chemistry

Pfizer Global Research and Development

United Kingdom

Postdoctoral Fellow :: Chemistry

University of Oxford

United Kingdom

Postdoctoral Research Assistant :: Chemistry

Education History

University of Manchester

United Kingdom

PHD :: Chemistry

University of Glasgow

United Kingdom

BSC :: Chemistry

Publications

Douglas S Williamson, Garrick P Smith, Gitte K Mikkelsen, Thomas Jensen, Pamela Acheson-Dossang, Lassina Badolo, Simon T Bedford, Victoria Chell, I-Jen Chen, Pawel Dokurno, Morten Hentzer, Samantha Newland, Stuart C Ray, Terry Shaw, Allan E Surgenor, Lindsey Terry, Yikang Wang, Kenneth Vielsted Christensen
Design and Synthesis of Pyrrolo[2,3-d]pyrimidine-Derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Checkpoint Kinase 1 (CHK1)-Derived Crystallographic Surrogate. Journal of medicinal chemistry 64 (14) (2021)
Douglas S Williamson, Garrick P Smith, Pamela Acheson-Dossang, Simon T Bedford, Victoria Chell, I-Jen Chen, Justus C A Daechsel, Zoe Daniels, Laurent David, Pawel Dokurno, Morten Hentzer, Martin C Herzig, Roderick E Hubbard, Jonathan D Moore, James B Murray, Samantha Newland, Stuart C Ray, Terry Shaw, Allan E Surgenor, Lindsey Terry, Kenneth Thirstrup, Yikang Wang, Kenneth Vielsted Christensen
Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). Journal of medicinal chemistry 60 (21) (2017)
Kenneth Thirstrup, Justus C Dächsel, Felix S Oppermann, Douglas S Williamson, Garrick P Smith, Karina Fog, Kenneth V Christensen
Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells. Scientific reports 7 (1) (2017)